Skip to main content

Table 2 Toxicities by maximum NCI CTC version 2.0 grade for each treatment arm (N, number of patients)

From: Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer

 

Group

mFOLFOX6

CAPOX

Grade

Grade

 

1

2

3

4

1

2

3

4

Hemoglobin

N

115

10

1

.

105

21

2

.

 

%

58.4

5.1

0.5

.

49.7

9.9

0.9

.

Leucocytes

N

65

60

5

.

77

35

5

.

 

%

33.0

30.4

2.5

.

36.5

16.6

2.4

.

Neutrophils

N

22

57

40

13

61

48

16

1

 

%

11.2

28.9

20.3

6.6

28.9

22.7

7.6

0.5

Febrile neutropenia

N

1

.

.

.

.

.

2

.

 

%

0.5

.

.

.

.

.

0.9

.

Platelets

N

75

26

5

.

70

32

7

.

 

%

38.1

13.2

2.5

 

33.2

15.2

3.31

.

Nausea

N

34

9

2

.

36

13

3

.

 

%

17.3

4.6

1.0

 

17.1

6.2

1.4

 

Vomiting

N

17

14

.

.

19

13

5

1

 

%

8.6

7.1

  

9.0

6.2

2.4

0.5

Mucositis

N

9

3

2

.

4

1

.

.

 

%

4.6

1.5

1.0

 

1.9

0.5

  

Diarrhea

N

26

12

6

2

27

28

12

3

 

%

13.2

6.1

3.0

1.0

12.8

13.0

5.7

1.4

Constipation

N

19

4

.

.

15

5

.

.

 

%

9.6

2.0

  

7.6

2.4

  

Liver toxicity

N

71

17

2

.

69

7

.

.

 

%

36.0

8.6

1.0

 

32.7

3.3

  

Neuropathy

N

59

43

14

.

66

44

9

.

 

%

29.9

21.8

7.1

 

31.2

20.8

4.3

 

HandFoot

N

4

1

.

.

10

3

1

.

%

2.1

0.5

  

4.7

1.4

0.5

 

Alopecia

N

6

2

.

.

2

1

.

.

%

3.0

1.0

  

0.9

0.5

  

Allergic reaction

N

4

9

2

.

5

1

4

.

%

2.0

4.6

1.0

 

2.4

0.5

1.9

 

Fever

N

9

5

.

.

13

3

.

.

%

4.6

2.5

  

6.2

1.4

  

Infection

N

.

4

1

.

.

4

1

.

%

.

2.0

0.5

  

1.9

0.5

 

Fatigue

N

23

7

2

.

28

8

4

1

%

11.6

3.6

1.0

 

13.2

3.8

1.9

0.5

Dizzines

N

6

1

.

.

8

.

.

.

%

3.0

0.5

  

3.8

   

Musculoskeletal pain

N

5

2

.

.

7

2

.

.

%

2.5

1.0

  

3.3

0.9

  

Metabolic

N

18

.

.

.

17

2

.

.

%

9.1

   

8.1

0.9

  
  1. NCI CTC National Cancer Institute Common Toxicity Criteria
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us